NASDAQ:TBIO Telesis Bio (TBIO) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free TBIO Stock Alerts $0.33 +0.01 (+4.70%) (As of 01:53 PM ET) Add Compare Share Share Today's Range$0.31▼$0.3450-Day Range$0.31▼$0.7852-Week Range$0.30▼$3.01Volume127,776 shsAverage Volume629,884 shsMarket Capitalization$9.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Telesis Bio alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Telesis Bio Stock (NASDAQ:TBIO)Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system, that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits which contains the necessary building blocks and reagents, including proprietary gibson assembly branded reagents, for specific synthetic biology workflow applications. It also provides BioXp Select kits which offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications such as cloning, mRNA generation from plasmid and cell free amplification; BioXp Next Generation Sequencing kits which contains the necessary reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents necessary to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom gibson short oligo ligation assembly enzymatic DNA synthesis solutions, designed reduce timelines for constructing synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.Read More TBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TBIO Stock News HeadlinesApril 20, 2024 | uk.investing.comTelesis Bio appoints new CEO as founder steps downApril 18, 2024 | msn.comTelesis Bio announces leadership transition amid new commercial focusApril 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 18, 2024 | globenewswire.comTelesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadershipMarch 29, 2024 | msn.comTBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q4 2023March 28, 2024 | globenewswire.comTelesis Bio Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 3, 2024 | morningstar.comTelesis Bio Inc TBIOFebruary 26, 2024 | finance.yahoo.comTelesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial ResultsApril 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? February 26, 2024 | globenewswire.comTelesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial ResultsFebruary 24, 2024 | benzinga.comTelesis Bio Stock (NASDAQ:TBIO), Insider Trading ActivityFebruary 23, 2024 | investorplace.comWhy Is Telesis Bio (TBIO) Stock Up 29% Today?February 23, 2024 | msn.comToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayFebruary 18, 2024 | finance.yahoo.comTelesis Bio, Inc. (TBIO)February 6, 2024 | finance.yahoo.comTelesis Bio, Inc.'s (NASDAQ:TBIO) Shares Leap 38% Yet They're Still Not Telling The Full StoryFebruary 6, 2024 | finance.yahoo.comBeat the Market the Zacks Way: Hershey's, Telesis Bio, General Mills in FocusFebruary 6, 2024 | finance.yahoo.comTelesis Bio (TBIO) Reports Q1 Loss, Misses Revenue EstimatesFebruary 6, 2024 | finance.yahoo.comTelesis Bio First Quarter 2023 Earnings: EPS Beats Expectations, Revenues LagFebruary 6, 2024 | finance.yahoo.comThis Telesis Bio Insider Increased Their Holding In The Last YearJanuary 22, 2024 | msn.comToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayNovember 13, 2023 | msn.comTelesis Bio GAAP EPS of -$0.37, revenue of $5.6MNovember 13, 2023 | msn.comTelesis Bio GAAP EPS of -$0.37 misses by $0.04, revenue of $5.6M misses by $1.8MAugust 30, 2023 | markets.businessinsider.comTelesis Bio Appoints William Kullback CFOAugust 29, 2023 | seekingalpha.comTelesis Bio appoints William Kullback as CFOAugust 29, 2023 | markets.businessinsider.comTelesis Bio Appoints William J. Kullback Chief Financial OfficerAugust 11, 2023 | markets.businessinsider.comTelesis Bio (TBIO) Receives a Rating Update from a Top AnalystAugust 11, 2023 | msn.comBofA lowers rating on Telesis Bio to sector weight from overweightSee More Headlines Receive TBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:TBIO Previous SymbolNASDAQ:DNAY CUSIPN/A CIK1850079 Webtelesisbio.com Phone858-228-4115FaxN/AEmployees137Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,720,000.00 Net Margins-173.78% Pretax Margin-173.40% Return on Equity-176.47% Return on Assets-38.42% Debt Debt-to-Equity Ratio22.76 Current Ratio3.71 Quick Ratio3.22 Sales & Book Value Annual Sales$27.51 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book31.99Miscellaneous Outstanding Shares30,100,000Free Float20,771,000Market Cap$9.63 million OptionableOptionable Beta1.93 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Todd R. Nelson MBA (Age 57)Ph.D., Founder & Director Comp: $924.38kMr. Daniel G. Gibson Ph.D. (Age 47)Chief Technology Officer Comp: $590.37kMr. Robert H. Cutler (Age 56)Chief Legal Officer Comp: $568.58kMr. Eric Esser (Age 55)President, CEO, COO & Director Mr. William J. Kullback (Age 64)Chief Financial Officer Ms. Jen CarrollVice President of Investor RelationsMr. Decky Goodrich M.B.A.Senior Vice President of Corporate DevelopmentMs. Laura B. Puga M.B.A. (Age 44)Vice President of People & Culture Mr. Laurence WardenSenior Vice President of Engineering & InstrumentationRichard LepkeDirector of Investor RelationsMore ExecutivesKey CompetitorsPrecipioNASDAQ:PRPOTalis BiomedicalNASDAQ:TLISAccelerate DiagnosticsNASDAQ:AXDXCue HealthNASDAQ:HLTHSingular Genomics SystemsNASDAQ:OMICView All CompetitorsInstitutional OwnershipSimplex Trading LLCBought 37,800 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions TBIO Stock Analysis - Frequently Asked Questions How have TBIO shares performed in 2024? Telesis Bio's stock was trading at $0.3990 at the beginning of the year. Since then, TBIO stock has decreased by 19.8% and is now trading at $0.3199. View the best growth stocks for 2024 here. Are investors shorting Telesis Bio? Telesis Bio saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 100,400 shares, a drop of 55.6% from the March 15th total of 226,300 shares. Based on an average daily volume of 742,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.1% of the shares of the company are short sold. View Telesis Bio's Short Interest. When is Telesis Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TBIO earnings forecast. How were Telesis Bio's earnings last quarter? Telesis Bio, Inc. (NASDAQ:TBIO) posted its earnings results on Thursday, March, 28th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. The business had revenue of $6.98 million for the quarter. Telesis Bio had a negative trailing twelve-month return on equity of 176.47% and a negative net margin of 173.78%. What guidance has Telesis Bio issued on next quarter's earnings? Telesis Bio updated its fourth quarter 2023 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.0 million-$7.0 million, compared to the consensus revenue estimate of $9.5 million. What is Craig J. Tuttle's approval rating as Telesis Bio's CEO? 13 employees have rated Telesis Bio Chief Executive Officer Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among the company's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Telesis Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Telesis Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv). When did Telesis Bio IPO? Telesis Bio (TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Telesis Bio? Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TBIO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
